Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Christopher Bahdah Nahm

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0888-4499; OpenAlex author ID A5086008434. Sources: OpenAlex.

Their work

Papers
13 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 13

  1. Impact of postoperative pancreatic fistula (POPF) on long-term outcomes of patients who underwent pancreatic cancer resection: systematic review and meta-analy… Last author DOI 10.1016/j.suronc.2026.102459↗
  2. FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. First author DOI 10.1002/cam4.70500↗
  3. The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients' survival. Co-author DOI 10.1186/s12957-022-02803-y↗
  4. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resect… Co-author DOI 10.3390/cancers14153620↗
  5. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33368↗
  6. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Co-author DOI 10.1016/j.ejso.2021.04.005↗
  7. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Co-author DOI 10.1016/j.bbagen.2020.129682↗
  8. Neoadjuvant therapy for pancreatic cancer changes the composition of the pancreatic parenchyma. First author DOI 10.1016/j.hpb.2020.03.007↗
  9. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001472↗
  10. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. Co-author DOI 10.1016/j.ejso.2018.10.050↗
  11. Understanding the Pathophysiology of Psychological Distress and Pancreatic Cancer: A Systematic Review. First author DOI 10.1097/mpa.0000000000001016↗
  12. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume r… Co-author DOI 10.1016/j.ejso.2017.06.012↗
  13. Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis. First author DOI 10.18632/oncotarget.19928↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 12 shared papers, 2017–2025 · strength 1.41
  2. Anthony James Gill · 12 shared papers, 2017–2025 · strength 1.41
  3. Anubhav Mittal · 12 shared papers, 2017–2025 · strength 1.41
  4. Stephen John Clarke · 6 shared papers, 2017–2022 · strength 0.63
  5. Nick Pavlakis · 6 shared papers, 2017–2022 · strength 0.63
  6. Sumit Sahni · 4 shared papers, 2020–2025 · strength 0.61
  7. George Hruby · 4 shared papers, 2017–2022 · strength 0.41
  8. Malinda Itchins · 4 shared papers, 2017–2022 · strength 0.36
  9. Sarah Maloney · 3 shared papers, 2020–2021 · strength 0.34
  10. Terence C. Chua · 4 shared papers, 2017–2021 · strength 0.34
  11. Nigel Balfour Jamieson · 3 shared papers, 2019–2021 · strength 0.29
  12. Lee S. Kyang · 1 shared paper, 2026 · strength 0.26
  13. Vincent W. T. Lam · 1 shared paper, 2026 · strength 0.26
  14. Henry C. C. Pleass · 1 shared paper, 2026 · strength 0.26
  15. Adnan M. Nagrial · 1 shared paper, 2026 · strength 0.26
  16. Tony Pang · 1 shared paper, 2026 · strength 0.26
  17. Mark Wong · 1 shared paper, 2026 · strength 0.26
  18. Sooin Byeon · 1 shared paper, 2025 · strength 0.25
  19. Nathalie B. Rasko · 1 shared paper, 2025 · strength 0.25
  20. Emily K. Colvin · 2 shared papers, 2019–2022 · strength 0.22
  21. Maxwell A. Jambor · 1 shared paper, 2022 · strength 0.15
  22. Nadya Rykina-Tameeva · 1 shared paper, 2020 · strength 0.13
  23. Angela S. Y. Chou · 1 shared paper, 2022 · strength 0.13
  24. James A. Toft · 1 shared paper, 2021 · strength 0.12
  25. Josef Gillson · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.